Last friday (10/11), we presented our neurotoxicity and genotoxicity assays at the French Agency for Food and Safety (ANSES). The ANSES had organized a meeting between different public screening platform facilities,  who used high content screening technologies.

We were kindly invited to present our platforms, and how HCS Pharma is involved in the development of innovative assays. Those events are a good way to start new collaborations, and we want to thanks Kevin Hogeveen, from Fougères laboratory who organized this meeting.

As shown by AstraZeneca in nature reviews*, one third of safety failures along the drug discovery process is linked to CNS toxicity uncovered in clinical trials. To avoid this attrition, the potential neurotoxicity of any drug going through the blood brain barrier (BBB) needs to be assessed in the very early stages of new chemical entities (NCE) research. Neurotoxicity assays can be performed on the SH-SY5Y human cell line by using High-Content Screening (HCS) technologies. The present study was performed using classical 2D and 3D culture protocols. In this poster, 2D results and preliminary 3D culture results on multiple reference compounds are depicted.

View and download on Slideshare (low quality) : https://www.slideshare.net/hcspharma/in-vitro-dermocosmetology-high-content-analysis-approach-using-human-primary-keratinocytes-and-fibroblasts

Ask for high quality link  by putting your email below

From 28 March to 1st April, the conference on DYRK1A and related kinases and human disease was held in Saint Malo. We have really enjoyed our venue as a sponsor of this conference. Thanks to the organizers, specially to Laurent Meijer and Pauline Demaison, we had a chance to present our services to the scientific community working on DYRKs protein. During 3 days, we have seen a lot of high quality scientific presentations from chemistry to the development of treatments for DYRKs related disease. We hope all these talks from international researchers will lead to scientific improvements in DIRK related disease.

The development of cellular models, especially in neurotoxicity, is an approach used to accelerate the development of new therapeutics for DYRK related disease. With our progress in 3D models, HCS Pharma hopes to provide new tools for researchers to better understand DYRKs protein,  and perhaps participate as a speakers at the next DYRK conference !

To see our assay in neurotoxicity just click here : http://hcs-pharma.com/services/toxicology/neurotox/

As shown by AstraZeneca in nature reviews, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs . To avoid this attrition, the potential neurotoxicity  of any drug going through the blood brain barrier (BBB) needs to be checked and if possible at the early stage of  the research process for new chemical entites (NCE). This assay can be performed by cell imaging in HCA/HCS.

View and download on Slideshare (low quality) :
http://fr.slideshare.net/hcspharma/neurotoxicity-assay-using-high-content-screening-technology

Ask for high quality link  by putting your email below

%d bloggers like this: